Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Sterol analysis identified four Candida albicans erg3 mutants in which ergosta 7,22-dienol, indicative of perturbations in sterol Δ 5,6 -desaturase (Erg3p) activity, comprised >5% of the total sterol fraction. The erg3 mutants (CA12, CA488, CA490, and CA1008) were all resistant to fluconazole, voriconazole, itraconazole, ketoconazole, and clotrimazole under standard CLSI assay conditions (MIC values, ≥256, 16, 16, 8, and 1 μg ml −1 , respectively). Importantly, CA12 and CA1008 retained an azole-resistant phenotype even when assayed in the presence of FK506, a multidrug efflux inhibitor. Conversely, CA488, CA490, and three comparator isolates (CA6, CA14, and CA177, in which ergosterol comprised >80% of the total sterol fraction and ergosta 7,22-dienol was undetectable) all displayed azole-sensitive phenotypes under efflux-inhibited assay conditions. Owing to their ergosterol content, CA6, CA14, and CA177 were highly sensitive to amphotericin B (MIC values, <0.25 μg ml −1 ); CA1008, in which ergosterol comprised <2% of the total sterol fraction, was less sensitive (MIC, 1 μg ml −1 ). CA1008 harbored multiple amino acid substitutions in Erg3p but only a single conserved polymorphism (E266D) in sterol 14α-demethylase (Erg11p). CA12 harbored one substitution (W332R) in Erg3p and no residue changes in Erg11p. CA488 and CA490 were found to harbor multiple residue changes in both Erg3p and Erg11p. The results suggest that missense mutations in ERG3 might arise in C. albicans more frequently than currently supposed and that the clinical significance of erg3 mutants, including those in which additional mechanisms also contribute to resistance, should not be discounted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Erg11, a cytochrome P450 enzyme, catalyzes the 14-methylation of lanosterol in C. albicans through three cycles13,14, each requiring two electrons from nicotinamide adenine dinucleotide phosphate (NADPH)-dependent Ncp1 reductase15,16.”
From Impairing the interaction between Erg11 and cytochrome P450 reductase Ncp1 enhances azoles’ antifungal activities (2025) · cites this paper as [13]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lower abundance of the enzyme has been observed in polyene-resistant species, which has been attributed to mutations in ERG2 [61,112], ERG3 [51], ERG5 [60], ERG6 [113], and ERG11 [60] genes, which encode enzymes involved in ergosterol synthesis.”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“several mutant ERG3 clinical isolates have been identified and reportedly possess resistance to the azole antifungals and cross-resistance to the polyene amphotericin B.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [142]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired resistance is also rare, and involves reduced ergosterol biosynthesis and the production of alternative sterols to which amphotericin B has low affinity.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the latest cross-resistance between amphotericin B and azoles or caspofungin in Candida species are increasingly worrying [103,194,195,196,197].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [195]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 3×
“Following extensive use, resistance to antifungal azoles first emerged in HIV-positive patients (29, 31); resistant isolates are now isolated from other clinical settings, including chemotherapy and organ transplantation.”
Saville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 1×
“Ergosterol maintains the integrity and fluidity of cell membranes (1) and consequently is understood to affect the morphology (20), virulence (30), and resistance characteristics of fungal pathogens.”
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398 · cited 6×
“b 14 -methylergosta-8,24(28)-dien-3 ,6 -diol.”
InfluentialMarichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351
Self-citationFranz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Self-citation
Research works printed but not linked: 2
- 10. Kelly, S., D. C. Lamb, and D. E. Kelly. 1999. Antifungal efflux; a major mechanism of resistance in fungi. J. Antimicrob. Chemother. 44: 36-37.
- 32. Wang, W., D. Wang, R. Y. Li, et al. 1999. A study of the resistant mechanisms of Candida albicans to azole antifungal agents. Chin. J. Derm. Venereol. 13: 3-5.
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
“albicans and Candida dubliniensis [45, 62, 64, 65].”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Metadata
- Authors
- Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L.
- Affiliations
- Swansea University (GB)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Kelly, Steven L.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-11
- Volume
- 54
- Issue
- 11
- Pages
- 4527-4533
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2976150
- OpenAlex
- W2109056652
- Cited by
- 168
- References
- 39
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 12 · 2019: 13 · 2018: 11 · 2017: 21 · 2016: 8 · 2015: 4 · 2014: 13 · 2013: 10 · 2012: 9
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Funders
- Engineering and Physical Sciences Research Council
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, sterol 14α-demethylase, ergosterol, fluconazole resistance, voriconazole resistance, ketoconazole resistance, clotrimazole resistance, amphotericin B susceptibility, FK506, efflux pump inhibition, missense mutations, antifungal resistance
- MeSH terms
- Amphotericin B, Antifungal Agents, Azoles, Candida albicans, Clotrimazole, Ergosterol, Ketoconazole, Microbial Sensitivity Tests, Mutation, Oxidoreductases, Pyrimidines, Triazoles, Fluconazole, Itraconazole, Drug Resistance, Fungal, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.